K
8.18
0.27 (3.41%)
| Penutupan Terdahulu | 7.91 |
| Buka | 7.90 |
| Jumlah Dagangan | 287,477 |
| Purata Dagangan (3B) | 704,362 |
| Modal Pasaran | 358,252,672 |
| Harga / Buku (P/B) | 2.53 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| EPS Cair (TTM) | -3.24 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.10% |
| Nisbah Semasa (MRQ) | 7.44 |
| Aliran Tunai Operasi (OCF TTM) | -133.64 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -80.19 M |
| Pulangan Atas Aset (ROA TTM) | -31.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.72% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Kyverna Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.50 |
|
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 12.04% |
| % Dimiliki oleh Institusi | 68.57% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Vida Ventures Advisors, Llc | 30 Sep 2025 | 4,523,924 |
| Insight Holdings Group, Llc | 30 Sep 2025 | 989,054 |
| Mbb Public Markets I Llc | 30 Sep 2025 | 614,477 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 31.00 (Wells Fargo, 278.97%) | Beli |
| Median | 25.00 (205.62%) | |
| Rendah | 20.00 (HC Wainwright & Co., 144.50%) | Beli |
| Purata | 25.33 (209.66%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 7.47 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 04 Dec 2025 | 25.00 (205.62%) | Beli | 7.84 |
| Wells Fargo | 30 Oct 2025 | 31.00 (278.97%) | Beli | 6.75 |
| 08 Oct 2025 | 27.00 (230.07%) | Beli | 7.18 | |
| HC Wainwright & Co. | 27 Oct 2025 | 20.00 (144.50%) | Beli | 7.81 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |